血管生成素样蛋白4是COVID-19严重程度的新型标志物
这项前瞻性多中心队列研究纳入2020年4月至2021年5月三家医学中心(华盛顿大学、南加州大学、纽约大学)ICU收治的225例COVID-19患者,于入ICU第1、7、14天检测血浆ANGPTL4。校正后每log2升高的ANGPTL4与住院死亡风险升高相关(校正OR 1.53,95%CI 1.17-2.00,p=0.002),并与静脉血栓栓塞和急性呼吸窘迫综合征比例升高相关;死亡者与存活者前2周ANGPTL4纵向变化显著不同(交互p=8.1×10⁻⁵)。组织蛋白组学显示COVID-19肺组织中ANGPTL4丰度高于其他器官,单核RNA测序显示COVID-19肺组织肺泡2型上皮细胞和成纤维细胞ANGPTL4基因表达较对照显著升高。作者结论认为ANGPTL4在肺上皮细胞和成纤维细胞表达,与危重COVID-19患者临床预后相关。
要点
- 225例COVID-19 ICU患者中,血浆ANGPTL4每升高1个log2,校正住院死亡OR为1.53(95%CI 1.17-2.00,p=0.002)。
- ANGPTL4较高者静脉血栓栓塞与急性呼吸窘迫综合征比例也较高。
- 死亡者与存活者住院前2周ANGPTL4纵向浓度差异显著(交互p=8.1×10⁻⁵)。
- COVID-19肺组织ANGPTL4蛋白丰度高于其他器官,肺泡2型上皮细胞和成纤维细胞ANGPTL4基因表达较对照显著升高。
适用人群与场景
- 2020年4月至2021年5月三家医学中心(华盛顿大学、南加州大学、纽约大学)ICU收治的225例COVID-19患者。
研究设计与关键结果
- 研究类型:前瞻性、多中心队列研究,纳入三家医学中心225例COVID-19 ICU患者,于入ICU第1、7、14天检测血浆ANGPTL4。
- 主要结果:血浆ANGPTL4每log2升高的校正住院死亡OR为1.53(95%CI 1.17-2.00,p=0.002)。
- ANGPTL4较高者静脉血栓栓塞和急性呼吸窘迫综合征比例较高。
- 死亡者与存活者住院前2周ANGPTL4纵向浓度差异显著(交互p=8.1×10⁻⁵)。
- 蛋白组学显示COVID-19肺组织ANGPTL4丰度高于其他器官;单核RNA测序显示COVID-19肺组织肺泡2型上皮细胞和成纤维细胞ANGPTL4基因表达较对照显著升高。
证据类型、等级与局限
- 证据类型:前瞻性、多中心队列研究。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Vascular dysfunction and capillary leak are common in critically ill COVID-19 patients, but identification of endothelial pathways involved in COVID-19 pathogenesis has been limited. Angiopoietin-like 4 (ANGPTL4) is a protein secreted in response to hypoxic and nutrient-poor conditions that has a variety of biological effects including vascular injury and capillary leak.
OBJECTIVES: To assess the role of ANGPTL4 in COVID-19-related outcomes.
DESIGN SETTING AND PARTICIPANTS: Two hundred twenty-five COVID-19 ICU patients were enrolled from April 2020 to May 2021 in a prospective, multicenter cohort study from three different medical centers, University of Washington, University of Southern California and New York University.
MAIN OUTCOMES AND MEASURES: Plasma ANGPTL4 was measured on days 1, 7, and 14 after ICU admission. We used previously published tissue proteomic data and lung single nucleus RNA (snRNA) sequencing data from specimens collected from COVID-19 patients to determine the tissues and cells that produce ANGPTL4.
RESULTS: Higher plasma ANGPTL4 concentrations were significantly associated with worse hospital mortality (adjusted odds ratio per log2 increase, 1.53; 95% CI, 1.17-2.00; p = 0.002). Higher ANGPTL4 concentrations were also associated with higher proportions of venous thromboembolism and acute respiratory distress syndrome. Longitudinal ANGPTL4 concentrations were significantly different during the first 2 weeks of hospitalization in patients who subsequently died compared with survivors (p for interaction = 8.1 × 10-5). Proteomics analysis demonstrated abundance of ANGPTL4 in lung tissue compared with other organs in COVID-19. ANGPTL4 single-nuclear RNA gene expression was significantly increased in pulmonary alveolar type 2 epithelial cells and fibroblasts in COVID-19 lung tissue compared with controls.
CONCLUSIONS AND RELEVANCE: ANGPTL4 is expressed in pulmonary epithelial cells and fibroblasts and is associated with clinical prognosis in critically ill COVID-19 patients.
参考来源
- Bhatraju PK, Morrell ED, Stanaway IB, et al. Angiopoietin-Like4 Is a Novel Marker of COVID-19 Severity. Crit Care Explor. 2022. PMID: 36600780. doi:10.1097/CCE.0000000000000827
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。